Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of NNC0268-0965 (Insulin 965) in Healthy and Type 1 Diabetes Subjects
NCT03965013Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nnc0268-0965 in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment-emergent adverse events. Started Jun 2019; status: completed.
02
Drugs
nnc0268-0965
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03965013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965013.